Patient and Disease–Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production of limitless supply of patient-specific somatic cells that enable advancement in cardiovascular precision medicine. Over the past decade, researchers have developed protocols to differentiate iPSCs to multiple cardiovascular lineages, as well as to enhance the maturity and functionality of these cells. Despite significant advances, drug therapy and discovery for cardiovascular disease have lagged behind other fields such as oncology. We speculate that this paucity of drug discovery is due to a previous lack of efficient, reproducible, and translational model systems. Notably, existing drug discovery and testing platforms rely on animal studies and clinical trials, but investigations in animal models have inherent limitations due to interspecies differences. Moreover, clinical trials are inherently flawed by assuming that all individuals with a disease will respond identically to a therapy, ignoring the genetic and epigenomic variations that define our individuality. With ever-improving differentiation and phenotyping methods, patient-specific iPSC-derived cardiovascular cells allow unprecedented opportunities to discover new drug targets and screen compounds for cardiovascular disease. Imbued with the genetic information of an individual, iPSCs will vastly improve our ability to test drugs efficiently, as well as tailor and titrate drug therapy for each patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979 · cited 1×
“…al., 2019; Wu et al., 2019a), dilated cardiomyopathy (Sun et al., 2012; Wu et al., 2015; Lee et al., 2019a), Brugada Syndrome (Liang et al., 2016; Belbachir et al., 2019), left ventricular noncompaction (Kodo et al., 2016), LEOPARD syndrome (Carvajal-Vergara et al., 2010), and arrhythmogenic…”
BackgroundSchwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065 · cited 1×
“Patients often requiremore than one hypertensive agent to control their blood pressure (Jamerson et al., 2008).”
BackgroundLosartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
Lian, X., Zhang, J., Azarin, S. M., Zhu, K., Hazeltine, L. B., Bao, X., Hsiao, C., Kamp, T. J., & Palecek, S. P. (2013) · Nature Protocols · doi:10.1038/nprot.2012.150 · Cited by 1,748
Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L. B., Azarin, S. M., Raval, K. K., Zhang, J., Kamp, T. J., & Palecek, S. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200250109 · Cited by 1,717
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606
Self-citationInduced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525 · cited 1×
“Dronedarone thus failed to live up to its billing as a rhythm control medication equally efficacious to amiodarone (Touboul et al., 2003; Singh et al., 2007; Davy et al., 2008); moreover, dronedarone was found to be deleterious by resulting in heart failure and chronic atrial fibrillation and was…”
BackgroundSelf-citationHypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Marian, A. J., & Braunwald, E. (2017) · Circulation Research · doi:10.1161/circresaha.117.311059 · Cited by 1,403 · cited 1×
“Approaches to create three-dimensional cardiac tissue (Eder et al., 2016; Mathur et al., 2016) and to stimulate the cells with mechanical and electrical stimuli (Chan et al., 2013; Ruan et al., 2016) have also been reported.”
BackgroundAdvanced maturation of human cardiac tissue grown from pluripotent stem cells
Ronaldson-Bouchard, K., Ma, S. P., Yeager, K., Chen, T., Song, L., Sirabella, D., Morikawa, K., Teles, D., Yazawa, M., & Vunjak-Novakovic, G. (2018) · Nature · doi:10.1038/s41586-018-0016-3 · Cited by 1,272
Modelling the long QT syndrome with induced pluripotent stem cells
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., Feldman, O., Gepstein, A., Arbel, G., Hammerman, H., et al. (2011) · Nature · doi:10.1038/nature09747 · Cited by 1,049
Engineering Adolescence: Maturation of Human Pluripotent Stem Cell–Derived Cardiomyocytes
Yang, X., Pabon, L., & Murry, C. E. (2014) · Circulation Research · doi:10.1161/circresaha.114.300558 · Cited by 939 · cited 2×
“Attempts to improve the maturation of iPSC-CMs include prolonged culture duration, treatment with triiodothyronine (T3) or dexamethasone (DEX), culture substrate variations, three-dimensional tissue engineering, electrical stimulation, and genetic approaches (Yang et al., 2014; Bedada et al., 2016; Tu et al., 2018).”
BackgroundStructural and Functional Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells
Lundy, S. D., Zhu, W.-Z., Regnier, M., & Laflamme, M. A. (2013) · Stem Cells and Development · doi:10.1089/scd.2012.0490 · Cited by 738 · cited 1×
“Recently, iPSCs have been used to assess whether genetic variants in individual patients are pathogenic or benign (Garg et al., 2018; Ma et al., 2018) and have proven useful in patient-specific drug screening and drug toxicity testing (Burridge et al., 2016; Matsa et al., 2016; Sharma et al., 2017,…”
MethodPatient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy
Sun, N., Yazawa, M., Liu, J., Han, L., Sanchez-Freire, V., Abilez, O. J., Navarrete, E. G., Hu, S., Wang, L., Lee, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003552 · Cited by 696
Self-citationPatient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Carvajal-Vergara, X., Sevilla, A., D’Souza, S. L., Ang, Y.-S., Schaniel, C., Lee, D.-F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., et al. (2010) · Nature · doi:10.1038/nature09005 · Cited by 690
Growth of engineered human myocardium with mechanical loading and vascular coculture
Tulloch, N. L., Muskheli, V., Razumova, M. V., Korte, F. S., Regnier, M., Hauch, K. D., Pabon, L., Reinecke, H., & Murry, C. E. (2011) · Circulation Research · doi:10.1161/circresaha.110.237206 · Cited by 666
Lopaschuk, G. D., & Jaswal, J. S. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181e74a14 · Cited by 636
Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.542738 · Cited by 614 · cited 1×
“For example, colchicine is an anti-inflammatory drug for gout, which found off-label use in other inflammatory conditions such as pericarditis and postoperative pericarditis syndrome (Imazio et al., 2005, 2013).”
BackgroundA Randomized Trial of Colchicine for Acute Pericarditis
Imazio, M., Brucato, A., Cemin, R., Ferrua, S., Maggiolini, S., Beqaraj, F., Demarie, D., Forno, D., Ferro, S., Maestroni, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208536 · Cited by 611
Pluripotent stem cells in disease modelling and drug discovery
Avior, Y., Sagi, I., & Benvenisty, N. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.27 · Cited by 592
Drug development in the era of precision medicine
Dugger, S. A., Platt, A., & Goldstein, D. B. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.226 · Cited by 493
Shadrin, I. Y., Allen, B. W., Qian, Y., Jackman, C. P., Carlson, A. L., Juhas, M. E., & Bursac, N. (2017) · Nature Communications · doi:10.1038/s41467-017-01946-x · Cited by 420
Insulin Causes Endothelial Dysfunction in Humans: Sites and Mechanisms
Arcaro, G., Cretti, A., Balzano, S., Lechi, A., Muggeo, M., Bonora, E., & Bonadonna, R. C. (2002) · Circulation · doi:10.1161/hc0502.103333 · Cited by 407 · cited 2×
“Recent studies have described how to modulate retinoic acid signaling during CM differentiation to derive atrial- and ventricular-like CMs (Lee et al., 2017a; Argenziano et al., 2018; Zhao et al., 2019), as well as sinoatrial nodal pacemaker cell CMs (Protze et al., 2017).”
BackgroundSharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2584 · Cited by 404 · cited 4×
“…iPSCs have been used to assess whether genetic variants in individual patients are pathogenic or benign (Garg et al., 2018; Ma et al., 2018) and have proven useful in patient-specific drug screening and drug toxicity testing (Burridge et al., 2016; Matsa et al., 2016; Sharma et al., 2017, 2018).”
BackgroundMethodInfluentialSelf-citationProtze, S. I., Liu, J., Nussinovitch, U., Ohana, L., Backx, P. H., Gepstein, L., & Keller, G. M. (2017) · Nature Biotechnology · doi:10.1038/nbt.3745 · Cited by 366
Generation of blood vessel organoids from human pluripotent stem cells
Wimmer, R. A., Leopoldi, A., Aichinger, M., Kerjaschki, D., & Penninger, J. M. (2019) · Nature Protocols · doi:10.1038/s41596-019-0213-z · Cited by 317
Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy
Gerdes, A. M., Kellerman, S. E., Moore, J. A., Muffly, K. E., Clark, L. C., Reaves, P. Y., Malec, K. B., McKeown, P. P., & Schocken, D. D. (1992) · Circulation · doi:10.1161/01.cir.86.2.426 · Cited by 307
Friedman, C. E., Nguyen, Q., Lukowski, S. W., Helfer, A., Chiu, H. S., Miklas, J., Levy, S., Suo, S., Han, J.-D. J., Osteil, P., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.09.009 · Cited by 258
Drawnel, F. M., Boccardo, S., Prummer, M., Delobel, F., Graff, A., Weber, M., Gérard, R., Badi, L., Kam-Thong, T., Bu, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.055 · Cited by 247 · cited 1×
“Rational drug design can be used to synthesize a multitude of compound (Drews, 2000).”
BackgroundNull mutations in human and mouse orthologs frequently result in different phenotypes
Liao, B.-Y., & Zhang, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800387105 · Cited by 234
Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy
Lee, J., Termglinchan, V., Diecke, S., Itzhaki, I., Lam, C. K., Garg, P., Lau, E., Greenhaw, M., Seeger, T., Wu, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1406-x · Cited by 222
Self-citationRibeiro, M. C., Tertoolen, L. G., Guadix, J. A., Bellin, M., Kosmidis, G., D'Aniello, C., Monshouwer-Kloots, J., Goumans, M.-J., Wang, Y.-L., Feinberg, A. W., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.01.067 · Cited by 214
Theodoris, C. V., Li, M., White, M. P., Liu, L., He, D., Pollard, K. S., Bruneau, B. G., & Srivastava, D. (2015) · Cell · doi:10.1016/j.cell.2015.02.035 · Cited by 210
Churko, J. M., Garg, P., Treutlein, B., Venkatasubramanian, M., Wu, H., Lee, J., Wessells, Q. N., Chen, S.-Y., Chen, W.-Y., Chetal, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07333-4 · Cited by 207 · cited 1×
“Such efforts are currently under development to model changes in hemodynamics and response to vascular inflammation or drug treatments using iPSC-derived vascular cells (Collado et al., 2017).”
BackgroundSelf-citationInduced pluripotent stem cells: at the heart of cardiovascular precision medicine
Chen, I. Y., Matsa, E., & Wu, J. C. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.36 · Cited by 191
Self-citationHuman engineered heart tissue as a model system for drug testing
Eder, A., Vollert, I., Hansen, A., & Eschenhagen, T. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.010 · Cited by 190
In vitro cardiac tissue models: Current status and future prospects
Mathur, A., Ma, Z., Loskill, P., Jeeawoody, S., & Healy, K. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.011 · Cited by 187 · cited 2×
“…iPSCs have been used to assess whether genetic variants in individual patients are pathogenic or benign (Garg et al., 2018; Ma et al., 2018) and have proven useful in patient-specific drug screening and drug toxicity testing (Burridge et al., 2016; Matsa et al., 2016; Sharma et al., 2017, 2018).”
BackgroundMethodZhang, H., Tian, L., Shen, M., Tu, C., Wu, H., Gu, M., Paik, D. T., & Wu, J. C. (2019) · Circulation Research · doi:10.1161/circresaha.119.315491 · Cited by 187
Self-citationWu, H., Lee, J., Vincent, L. G., Wang, Q., Gu, M., Lan, F., Churko, J. M., Sallam, K. I., Matsa, E., Sharma, A., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.04.020 · Cited by 177 · cited 2×
“…Garg et al., 2018), hypertrophic cardiomyopathy (Lan et al., 2013; Seeger et al., 2019; Wu et al., 2019a), dilated cardiomyopathy (Sun et al., 2012; Wu et al., 2015; Lee et al., 2019a), Brugada Syndrome (Liang et al., 2016; Belbachir et al., 2019), left ventricular noncompaction (Kodo et al.,…”
BackgroundSelf-citationMatsa, E., Burridge, P. W., Yu, K.-H., Ahrens, J. H., Termglinchan, V., Wu, H., Liu, C., Shukla, P., Sayed, N., Churko, J. M., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.07.006 · Cited by 164 · cited 1×
“Most prominently, type 2 diabetes (T2D) is a global epidemic affecting over 400 million people and is a leading cause of morbidity and mortality (Menke et al., 2015).”
BackgroundSelf-citationTzatzalos, E., Abilez, O. J., Shukla, P., & Wu, J. C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.010 · Cited by 162
Self-citationBraunwald, E. (2017) · Circulation Research · doi:10.1161/circresaha.117.311812 · Cited by 150 · cited 2×
“Hypertrophic cardiomyopathy (HCM) is an abnormal thickening of the ventricle that causes microinfarction, outflow tract obstruction, and scarring, resulting in arrhythmias (Marian and Braunwald, 2017).”
BackgroundSiu, C.-W., Lee, Y.-K., Ho, J. C.-Y., Lai, W.-H., Chan, Y.-C., Ng, K.-M., Wong, L.-Y., Au, K.-W., Lau, Y.-M., Zhang, J., et al. (2012) · Aging · doi:10.18632/aging.100503 · Cited by 141
Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models
Wnorowski, A., Yang, H., & Wu, J. C. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.001 · Cited by 124
Self-citationLee, S., Huh, J. Y., Turner, D. M., Lee, S., Robinson, J., Stein, J. E., Shim, S. H., Hong, C. P., Kang, M. S., Nakagawa, M., et al. (2018) · Stem Cells · doi:10.1002/stem.2865 · Cited by 99
Murine "model" monotheism: an iconoclast at the altar of mouse
Libby, P. (2015) · Circulation Research · doi:10.1161/circresaha.115.307523 · Cited by 60
Lam, C. K., Tian, L., Belbachir, N., Wnorowski, A., Shrestha, R., Ma, N., Kitani, T., Rhee, J.-W., & Wu, J. C. (2019) · Circulation Research · doi:10.1161/circresaha.118.314202 · Cited by 39
Self-citation
Cited by
Single-cell RNA sequencing in cardiovascular development, disease and medicine
Paik, D. T., Cho, S., Tian, L., Chang, H. Y., & Wu, J. C. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0359-y · Cited by 307
Self-citationOlgasi, C., Cucci, A., & Follenzi, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176215 · Cited by 100
“The iPSC technology also allows for the screening of a library of human cell lines, which may represent the genetic and potentially epigenetic variations covering of a broad spectrum of the population [14], that can be useful both for preclinical drug discovery and the development of personalized medicine [15,16].”
BackgroundRepurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
Parrotta, E. I., Lucchino, V., Scaramuzzino, L., Scalise, S., & Cuda, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124354 · Cited by 88
“Even if the use of patient-specific iPSC-based platforms in drug discovery and personalized medicine is advantageous for many aspects, they are not yet completely affirmed in the pharmaceutical industry due to the time-consuming nature and high cost of iPSC production and differentiation processes [99].”
BackgroundRevolutionizing Disease Modeling: The Emergence of Organoids in Cellular Systems
Silva-Pedrosa, R., Salgado, A. J., & Ferreira, P. E. (2023) · Cells · doi:10.3390/cells12060930 · Cited by 84
“This can help to avoid immune rejection of the transplanted cells [31]; • Disease modeling: iPSCs can be used to create models of specific diseases, which can aid in the understanding of the disease and the development of new treatments [18]; • Drug development: iPSCs can be used to test the safety and efficacy of new…”
Result
Metadata
- Authors
- Paik, D. T., Chandy, M., & Wu, J. C.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 72
- Issue
- 1
- Pages
- 320-342
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2998633251
- Cited by
- 216
- References
- 59
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.